Regorafenib in Advanced and Refractory Gastrointestinal Cancers - European Medical Journal
×

Browse

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

| Download as | PDF
Speakers:
Eric Van Cutsem,1 Michael Ducreux,2 Diether Lambrechts3
Disclosure:

Prof Eric Van Cutsem has received research funding from Amgen, Bayer, Boehringer Ingelheim, Lilly, Merck Serono, Novartis, Roche, and Sanofi. Dr Diether Lambrechts has served on advisory boards for Roche, Sanofi, Bayer, and Boehringer-Ingelheim, and received speaker’s fees from Eli Lilly and Roche. Dr Michel Ducreux has received research funding from Roche, Chugai, and Pfizer, and has other substantive relationships with Celgene, Merck Serono, Amgen, Novartis, and Sanofi.

Acknowledgements:

Medical writing was provided by Ewen Legg, PhD, of Halcyon Medical Writing and was funded by Bayer.

Support:

Medical writing was provided by Ewen Legg, PhD, of Halcyon Medical Writing and was funded by Bayer.

Citation
EMJ. ;1[3]:21-25.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The European Society for Medical Oncology’s (ESMO) 18th World Congress on Gastrointestinal Cancer (WCGI) was held in Barcelona from 28th June–2nd July 2016. Presentations covered gastrointestinal (GI) cancers of every aetiology and site within the GI tract, as well as the major aspects of cancer management from screening to novel therapeutic options. Tyrosine kinase inhibitors (TKIs), with their ability to block key mechanisms required for tumour growth, featured heavily in this year’s presentations at WCGI. Data on the oral TKI regorafenib featured prominently in both poster discussion tours and oral presentations, emphasising the continuing interest in the evolution of this therapy within the clinical arsenal of physicians tackling GI cancers.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.